Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression

Autor: Boris Revollo, Laura Viñuela, Lorena de la Mora, Federico García, Marc Noguera-Julián, Mariona Parera, Roger Paredes, Josep M. Llibre
Rok vydání: 2022
Předmět:
Zdroj: Journal of Antimicrobial Chemotherapy
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
ISSN: 1460-2091
0305-7453
DOI: 10.1093/jac/dkac082
Popis: Objectives Integrase resistance has not been reported with co-formulated dolutegravir/lamivudine in clinical trials or real-life cohorts. We aim to report, to the best of our knowledge, the first case of selection of the key integrase mutation R263K in a subject treated with this regimen started as a switch strategy with undetectable plasma HIV-1 viraemia. Methods Clinical case report. Results A patient with long-term suppressed HIV-1 viraemia ( Conclusions This case illustrates that integrase resistance can emerge in patients treated with co-formulated dolutegravir/lamivudine and raises awareness of the need to carefully consider and monitor drug–drug interactions, even when regarded as having a low potential, in subjects treated with dolutegravir/lamivudine.
Databáze: OpenAIRE